Not provided
Not provided
Not provided
Not provided
Not provided
Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is conducted to investigate the pharmacokinetic and safety profiles of TQB3720 in patients with metastatic castration-resistant prostate cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TQB3720 tablets | Experimental | TQB3720 tablets administered orally, once daily in 28-day cycle. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TQB3720 | Drug | This is an androgen receptor antagonists. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum tolerated dose (MTD) | MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT. | Baseline up to 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax | Cmax is the maximum plasma concentration of TQB3720 or metabolite(s). | 0hour, 2hour, 4hour, 8hour, 12hour, 24hour, 36hour, 48hour, 72hour, 96hour,120hour post-dose on single dose; Hour 0 of day 8、day 15、day 22；0 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour post-dose on multiple dose of day 28; Hour 0 of day 42 and day 56. |
Not provided
Inclusion Criteria:
1. Histologically or cytologically confirmed prostate carcinoma. 2.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy ≥12 weeks.
3.Testosterone levels < 50 ng/dL. 4. Has received ≥1 previous regimens for metastatic castration-resistant prostate cancer.
5.Male subjects should agree to use an adequate method of contraception starting with signing ICF through 6 months after the last dose of study.
6.Understood and signed an informed consent form.
Exclusion Criteria:
-1.Has symptomatic brain metastases or control of symptoms < 1 month. 2.Has other malignancies within 3 years. 3.Has used second-generation androgen receptor antagonists. 4. Abnormal liver function. 5. Abnormal renal function. 6. Has received any other investigational drug within 30 days weeks before first dose.
7. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | Shanghai Municipality | 200035 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tmax |
To characterize the pharmacokinetics of TQB3720 by assessment of time to reach maximum plasma concentration. |
| 0hour, 2hour, 4hour, 8hour, 12hour, 24hour, 36hour, 48hour, 72hour, 96hour,120hour post-dose on single dose; Hour 0 of day 8、day 15、day 22；0 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour post-dose on multiple dose of day 28; Hour 0 of day 42 and day 56. |
| AUC0-t | To characterize the pharmacokinetics of TQB3720 by assessment of area under the plasma concentration time curve from zero to infinity. | 0hour, 2hour, 4hour, 8hour, 12hour, 24hour, 36hour, 48hour, 72hour, 96hour,120hour post-dose on single dose; Hour 0 of day 8、day 15、day 22；0 hour, 2 hour, 4 hour, 8 hour, 12 hour, 24 hour post-dose on multiple dose of day 28; Hour 0 of day 42 and day 56. |